- Home
- CYN vs ICCM Comparison
CYN vs ICCM Comparison
Compare CYN & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYN | ICCM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | Israel |
| Employees | 62 | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 20.4M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CYN | ICCM |
|---|---|---|
| Price | $1.15 | $3.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 237.8K | ★ 8.8M |
| Earning Date | 05-06-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $3,359.28 | $139.51 |
| Revenue Next Year | $347.47 | $75.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $0.13 |
| 52 Week High | $10.04 | $9.54 |
Technical Indicators
Market Signals| Indicator | CYN | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 38.14 | 47.10 |
| Support Level | $1.10 | $0.48 |
| Resistance Level | $1.40 | $5.69 |
| Average True Range (ATR) | 0.09 | 0.42 |
| MACD | -0.01 | -0.32 |
| Stochastic Oscillator | 8.33 | 6.67 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.